HighTower Advisors
ROIV icon

HighTower Advisors’s Roivant Sciences ROIV Stock Holding History

HighTower Advisors’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.11M Buy
30,301
+2,014
+7% +$73K ﹤0.01% 2206
2026
Q2 		$1M Sell
28,287
-5,377
-16% -$159K ﹤0.01% 2239
2026
Q1 		$932K Buy
33,664
+4,804
+17% +$123K ﹤0.01% 2232
2025
Q4 		$626K Buy
28,860
+3,673
+15% +$72.5K ﹤0.01% 2451
2025
Q3 		$381K Buy
25,187
+7,044
+39% +$87.2K ﹤0.01% 2836
2025
Q2 		$204K Buy
18,143
+4,211
+30% +$45.6K ﹤0.01% 3263
2025
Q1 		$141K Buy
13,932
+3,719
+36% +$40.2K ﹤0.01% 3283
2024
Q4 		$121K Buy
+10,213
New +$121K ﹤0.01% 3337
2023
Q1 		– Sell
-18,200
Closed -$146K – 3632
2022
Q4 		$146K Buy
+18,200
New +$101K ﹤0.01% 2865

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

HighTower Advisors's ROIV Position: Q3 2026 in Review

HighTower Advisors increased its Roivant Sciences (ROIV) stake by 7.1% in Q3 2026, buying an estimated $73K and bringing the position to 30,301 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2206.

HighTower Advisors first reported a position in ROIV in Q4 2022 and has held it in 9 quarters since. 395 funds tracked by Wall St. Rank hold ROIV as of Q3 2026.

  • HighTower Advisors held 30,301 shares of Roivant Sciences worth $1.11M as of Q3 2026.
  • HighTower Advisors bought 2,014 Roivant Sciences shares in Q3 2026, an estimated $73K.
  • Roivant Sciences made up ﹤0.01% of HighTower Advisors's portfolio in Q3 2026, its #2206 holding.
  • HighTower Advisors first reported a position in Roivant Sciences in Q4 2022 and has held it in 9 quarters since.
  • 395 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2026.

Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.